Altimmune announces publication of clinical study of pemvidutide in metabolic dysfunction-associated steatotic liver disease (masld) in journal of hepatology

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (lfc), with up to 55.6% of subjects achieving lfc normalization after 12 weeks of treatment
ALT Ratings Summary
ALT Quant Ranking